Non‐pharmacological biological treatment approaches to difficult‐to‐treat depression

  title={Non‐pharmacological biological treatment approaches to difficult‐to‐treat depression},
  author={P. Fitzgerald},
  journal={Medical Journal of Australia},
There has been substantial recent interest in novel brain stimulation treatments for difficult‐to‐treat depression. Electroconvulsive therapy (ECT) is a well established, effective treatment for severe depression. ECT's problematic side‐effect profile and questions regarding optimal administration methods continue to be investigated. Magnetic seizure therapy, although very early in development, shows promise, with potentially similar efficacy to ECT but fewer side effects. Vagus nerve… Expand

Topics from this paper

Pharmacological treatment approaches to difficult-to-treat depression.
There is no strong evidence for the order of implementing evidence-based pharmacological strategies for difficult-to-treat depression, but recommend: i) increase antidepressant dose; ii) switch to different antidepressant; iii) augment with a non-antidepressant agent; and iv) combine antidepressants. Expand
Managing inadequate antidepressant response in depressive illness.
Depression frequently fails to respond to initial treatment and strategies with the strongest support are antidepressant augmentation with lithium or second generation antipsychotics and adding cognitive behavioural treatment. Expand
Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: A nonrandomized controlled pilot study.
The results suggest that taVNS is a promising, safe, and cost-effective therapeutic method for mild and moderate MDD. Expand
Psychosocial treatment approaches to difficult-to-treat depression.
The evidence base for psychosocial therapies in difficult-to-treat depression is small, with the research heavily weighted toward biological treatments. Expand
Vagus Nerve Stimulation in children: A focus on intellectual disability.
It was showed that VNS was less effective in pediatric epilepsy patients with ID compared to those without ID, but current data do not exclude VNS for children with drug-resistant epilepsy and ID but should be interpreted with caution. Expand
Major depressive disorder
An overview of the current evidence of major depressive disorder, including its epidemiology, aetiology, pathophysiology, diagnosis and treatment, is provided. Expand
Brain Neuromodulation Techniques
With the current rapid growth in neuromodulation technologies and applications, it is timely to review the genesis of the field and the current state of the art in this area. Expand
Yoga for mental health : evaluation of yoga interventions for reducing depression and anxiety, and improving well-being
Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53
Necrosis, unregulated cell death, is characterized by plasma membrane rupture as well as nuclear and cellular swelling. However, it has recently been reported that necrosis is a regulated form ofExpand


Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression.
Characteristics in MST- and ECT-induced seizures were comparable, especially regarding ictal activity and postictal suppression, and MST may be a potential alternative to ECT if efficacy and safety are validated in larger clinical trials. Expand
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years.
Deep brain stimulation remains a safe and effective treatment for treatment-resistant depression and functional impairment in the areas of physical health and social functioning progressively improved up to the last follow-up visit. Expand
Vagus nerve stimulation in depression
Longer term data regarding symptomatic and functional outcomes of depressed patients receiving VNS continue to look promising, similar to findings in epilepsy and in contrast to the usual results of long-term medication trials. Expand
Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression
Bilateral EpCS over anterior and midlateral frontal cortex is a promising new technology for treatment-resistant depression and future double-blind studies are warranted. Expand
Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial
Findings confirm earlier reports of the antidepressant efficacy and safety of tDCS and Vigilance for mood switching is advised when administering tDCS to individuals with bipolar disorder. Expand
Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes
Longer-term vagus nerve stimulation treatment was associated with sustained symptomatic benefit and sustained or enhanced functional status in this naturalistic follow-up study. Expand
A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression.
There was a low incidence of accidental seizures and induced hypomania, both of which were associated with identified risk factors for which subjects should be screened, and supports its further development as a clinical treatment. Expand
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression
Deep brain stimulation of the VC/VS offers promise for the treatment of refractory major depression. Expand
Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial
Transcranial magnetic stimulation was effective in treating major depression with minimal side effects reported and offers clinicians a novel alternative for the treatment of this disorder. Expand
Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial.
Daily left prefrontal repetitive transcranial magnetic stimulation as monotherapy produced statistically significant and clinically meaningful antidepressant therapeutic effects greater than sham. Expand